Analysis by Optimly for Optimly AI Visibility, in the Optimly AI Brand Index. This Business Profile tracks the Brand Authority Index and supporting AI visibility evidence. Last analyzed August 9, 2026.

AstraZeneca PLC

What is AstraZeneca PLC?

AstraZeneca PLC is a company within the Pharmaceuticals & Biotechnology category. AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company operates in major therapeutic areas including Oncology, Rare Diseases, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Known for its 'What science can do' philosophy, it maintains major global R&D centers in the UK, Sweden, and the US.

When was AstraZeneca PLC founded and where is it based?

AstraZeneca PLC was founded in 1999 and is headquartered in Cambridge, UK.

What is AstraZeneca PLC's Brand Authority Index tier?

AstraZeneca PLC is rated Leader on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.

How accurately do AI models describe AstraZeneca PLC?

AI narrative accuracy for AstraZeneca PLC is Moderate. Significant factual deltas detected. Inconsistent representation across models.

How do AI models position AstraZeneca PLC competitively?

AI models classify AstraZeneca PLC as a Challenger. AI names competitors first.

How visible is AstraZeneca PLC in buyer-intent AI queries?

AstraZeneca PLC appeared in 7 of 8 sampled buyer-intent queries (88%). While the brand dominates technical medical queries, it faces a gap in 'next-generation' discovery where AI might prioritize newer biotech startups for cell therapy queries.

What do AI models currently say about AstraZeneca PLC?

The brand is perceived as a science-led global powerhouse with a heavy emphasis on innovation and 'what science can do.' While its historical identity is tied to broad-market medicine, AI increasingly recognizes its shift toward high-value specialty areas like rare diseases and cell therapy. Key gap: AI often focuses heavily on the COVID-19 vaccine legacy, whereas the brand's current identity is pivoting aggressively toward Rare Disease and Next Generation Therapeutics.

How many facts about AstraZeneca PLC are well-documented vs need fixing vs retrieval-dependent?

Of 6 key facts verified about AstraZeneca PLC, 4 are well-documented (likely accurate across AI models), 2 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.

What is AstraZeneca PLC's biggest AI narrative vulnerability?

The recency of financial data (Q1 2026) and specific pipeline counts (186) will likely lead to hallucinations or outdated figures in AI responses.

What problems does AstraZeneca PLC solve for buyers?

Buyers turn to AstraZeneca PLC for Lifestyle Management: Traditional lifestyle changes or diet-based interventions for chronic conditions before clinical diagnoses., Custom Research Solutions: Hiring specialized medical research firms or CROs for bespoke therapeutic development within a health system., among 2 documented problem areas.

What questions do buyers ask AI about AstraZeneca PLC?

Buyers evaluating AstraZeneca PLC typically ask AI models about "top oncology pharmaceutical companies", "biotech companies in Cambridge UK", "pharmaceutical companies focusing on rare diseases", and 3 similar queries.

What does AstraZeneca PLC offer?

AstraZeneca PLC's core products are Prescription medicines in Oncology, Rare Disease, CVRM, and Respiratory..

How is AstraZeneca PLC priced?

AstraZeneca PLC uses Enterprise/Custom (Healthcare systems & Insurance).

Who does AstraZeneca PLC target?

AstraZeneca PLC serves Global healthcare providers, hospitals, pharmacy benefit managers, and government health agencies..

What differentiates AstraZeneca PLC from competitors?

AstraZeneca PLC A massive, 'catalyst-rich' pipeline of 186 projects led by a science-first culture and a specific focus on high-value Phase III programs in Rare Disease and Oncology.

Brand Authority Index (BAI) tier: Leader (exact score locked for unclaimed brands)

Archetype: Challenger

Official website: https://astrazeneca.com/

Last analyzed: August 9, 2026

Verified public facts

Founded: 1999 (via merger) (source: official website)

Headquarters: Cambridge, United Kingdom (source: official website)

Problems this brand solves

Buyers search for

About this profile

This Business Profile is published by Optimly in the Optimly AI Brand Index, a public research dataset showing how AI systems describe brands, categories, and competitors. Optimly AI Visibility analyzes sampled buyer-intent responses, cited sources, and public brand information. The Brand Authority Index summarizes answer presence, narrative accuracy, and owned citations where sufficient evidence is available.

If this is your brand, you can claim this profile to verify its contents and correct what AI models say about you: Claim this profile